Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Return on Sales (2020 - 2025)

Maxcyte (MXCT) has disclosed Return on Sales for 6 consecutive years, with 2.7% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 64.0% to 2.7% in Q3 2025 year-over-year; TTM through Sep 2025 was 2.38%, a 104.0% decrease, with the full-year FY2024 number at 1.85%, up 10.0% from a year prior.
  • Return on Sales was 2.7% for Q3 2025 at Maxcyte, down from 1.45% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.26% in Q3 2021 to a low of 35.8% in Q4 2024.
  • A 5-year average of 3.21% and a median of 1.11% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: soared 284bps in 2023, then crashed -3469bps in 2024.
  • Maxcyte's Return on Sales stood at 0.48% in 2021, then fell by -29bps to 0.62% in 2022, then tumbled by -79bps to 1.11% in 2023, then tumbled by -3125bps to 35.8% in 2024, then surged by 92bps to 2.7% in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Return on Sales are 2.7% (Q3 2025), 1.45% (Q2 2025), and 1.79% (Q1 2025).